5036
document
Somatostatin and ranitidine in the treatment of non-variceal upper gastrointestinal bleeding : a prospective , randomized , double-blind , controlled study . BACKGROUND/AIMS The aim of this study was to compare the efficacy of somatostatin vs. ranitidine in controlling acute non-variceal gastrointestinal bleeding . METHODOLOGY A total of 48 patients with acute upper gastrointestinal bleeding due to duodenal or gastric ulcer were divided into 2 groups . Group I consisted of 15 patients with Forrest IB and Group II consisted of 30 patients with Forrest II . Two regimens were randomly allocated to all patients within half an hour after the endoscopic procedure : 1 ) somatostatin-UCB 250 mcg i.v . bolus followed by continuous i.v . infusion at a rate of 6 mg/d for 72 h , or 2 ) ranitidine 300 mg/d by continuous i.v . infusion for 72 h. RESULTS In Group I , although mean blood transfusion requirements ( no . of units ) were lower in patients treated with somatostatin than in those treated with ranitidine , this was not statistically significant ( mean +/- SD : 2.56 +/- 3.05 vs. 5.17 +/- 4.96 , respectively ; P > 0.05 ) ; the time of bleeding stop was shorter in the somatostatin group than in the ranitidine group ( mean +/- SD : 3.24 +/- 2.45 vs. 11.25 +/- 11.63 , respectively ; P = 0.0383 ) . The rebleeding and the mortality rates did not differ between the treatment groups in both Group I and Group II . CONCLUSIONS Somatostatin is more effective than ranitidine in controlling acute non-variceal gastrointestinal bleeding in patients with Forrest IB bleeding activity . Somatostatin has no additional benefit in those with Forrest II bleeding activity .
5037
Intervention_Pharmacological
Somatostatin and ranitidine
5038
Intervention_Pharmacological
somatostatin vs. ranitidine
5039
Intervention_Pharmacological
somatostatin-UCB
5040
Intervention_Pharmacological
ranitidine
5041
Intervention_Pharmacological
somatostatin
5042
Intervention_Pharmacological
ranitidine
5043
Intervention_Pharmacological
somatostatin
5044
Intervention_Pharmacological
Somatostatin
5045
Intervention_Pharmacological
Somatostatin
5046
Outcome_Other
efficacy
5047
Outcome_Physical
acute non-variceal gastrointestinal bleeding
5048
Outcome_Physical
blood transfusion requirements
5049
Outcome_Physical
time of bleeding stop
5050
Outcome_Physical
rebleeding
5051
Outcome_Mortality
mortality rates
5052
Outcome_Other
effective
5053
Outcome_Physical
acute non-variceal gastrointestinal bleeding
5054
Outcome_Other
additional benefit
5055
Participant_Condition
non-variceal upper gastrointestinal bleeding
5056
Participant_Condition
acute non-variceal gastrointestinal bleeding
5057
Participant_Condition
duodenal or gastric ulcer